Edition:
United States

Endologix Inc (ELGX.OQ)

ELGX.OQ on NASDAQ Stock Exchange Global Select Market

5.78USD
3:51pm EST
Change (% chg)

$0.11 (+1.94%)
Prev Close
$5.67
Open
$5.67
Day's High
$5.90
Day's Low
$5.64
Volume
62,589
Avg. Vol
183,223
52-wk High
$7.66
52-wk Low
$4.08

Summary

Name Age Since Current Position

Daniel Lemaitre

63 2017 Chairman of the Board

Robert Mitchell

55 2014 President

John McDermott

57 2017 Chief Executive Officer, Director

Vaseem Mahboob

48 2015 Chief Financial Officer, Corporate Secretary

John Onopchenko

59 2017 Chief Operating Officer

Michael Chobotov

56 2016 Chief Technology Officer

David Jennings

62 2013 Vice President - Human Resources

Amanda DePalma

45 2014 Vice President - Global Marketing

Meredith Huetter

43 2016 Vice President - Global Medical Affairs

Michael Maszy

40 2016 Vice President - Manufacturing

Laura Nagel

54 2017 Vice President - Global Quality

Jeffrey Stelk

54 2004 Vice President - U.S. Sales

W. Patrick Stephens

48 2016 Vice President - Research and Development

Joseph DeJohn

56 2015 General Manager - Asia/Pacific and Latin America

Matthew Thompson

55 2016 Chief Medical Officer

Christopher Chavez

61 2016 Independent Director

Guido Neels

68 2010 Independent Director

Leslie Norwalk

51 2015 Independent Director

Gregory Waller

67 2003 Independent Director

Thomas Wilder

53 2010 Independent Director

Thomas Zenty

61 2013 Independent Director

Biographies

Name Description

Daniel Lemaitre

Mr. Daniel T. Lemaitre serves as an Chairman of the Board of Endologix, Inc. Mr. Lemaitre served as our Lead Independent Director from March 2014 to February 2017, when the board appointed him as our Chairman. Mr. Lemaitre served as President and Chief Executive Officer of Direct Flow Medical, Inc., a privately-held medical device company, from May 2015 to November 2016. Prior to joining Direct Flow Medical, Mr. Lemaitre served as Chief Executive Officer of White Pine Medical, Inc., a privately-held medical device company, from June 2009 to May 2015. Prior to White Pine Medical, Mr. Lemaitre served as the President and Chief Executive Officer of CoreValve, a privately-held company focused on percutaneous aortic valve replacement, from April 2008 until its acquisition by Medtronic, Inc., a publicly-traded medical device company, in April 2009. From 2005 until March 2008, Mr. Lemaitre was a Senior Vice President at Medtronic, where he led the company’s strategic planning and corporate development. Prior to joining Medtronic, Mr. Lemaitre spent 28 years in the medical device field as an investment analyst. This included 18 years with SG Cowen, where he was a managing director and led the healthcare research team, and six years with Merrill Lynch. Mr. Lemaitre holds a B.A. in Economics from Bethany College and an M.B.A. from Bowling Green State University.

Robert Mitchell

Mr. Robert D. Mitchell is no longer President of Endologix, Inc effective December 31, 2017. Prior to joining us, Mr. Mitchell served as President and Chief Executive Officer of Nellix, Inc. from February 2008 until our acquisition of Nellix in December 2010. From November 2006 to February 2008, Mr. Mitchell served as Executive Vice President and Chief Operating Officer of AngioDynamics, Inc., a publicly-held medical device company. From 2005 to 2006, Mr. Mitchell served as Chairman, President and Chief Executive Officer of Millimed Holdings, Inc., a privately-held medical device company based in Roskilde, Denmark. From 2004 to 2005, Mr. Mitchell served as Vice President of Worldwide Sales for Align Technology, Inc., a publicly-held company. From 1987 to 2004, Mr. Mitchell held various positions with Cook Incorporated, a privately-held medical device company, including Vice President and Director, Global Sales and Marketing for various business units including diagnostic and interventional, endovascular, critical care. Mr. Mitchell holds a B.S. from the University of Utah and an M.B.A. from Indiana Wesleyan University.

John McDermott

Mr. John D. McDermott serves as Chief Executive Officer, Director of Endologix, Inc. Mr. McDermott has 25 years of executive management, sales, marketing, and finance experience in the vascular device industry. From 2002 to 2007 he served as President of Bard Peripheral Vascular, a division of C.R. Bard, Inc. Mr. McDermott previously served as President of Global Sales for C.R. Bard’s vascular surgery and endovascular businesses. Prior to that, he served for four years as President of C.R. Bard’s division IMPRA, Inc., where he was responsible for global operations, including sales, marketing, research and development, manufacturing, and finance. From 1990 to 1996, Mr. McDermott served as Chief Financial Officer and later Vice President and Chief Operating Officer of IMPRA, Inc., prior to its acquisition by C.R. Bard. He is an active leader within the vascular community and is currently on the board of directors of the International Society of Endovascular Specialists. Mr. McDermott holds a B.S. in Finance from Arizona State University and an M.B.A from Western International University.

Vaseem Mahboob

Mr. Vaseem Mahboob serves as Chief Financial Officer, Corporate Secretary of Endologix, Inc. Prior to joining us, Mr. Mahboob served for 16 years as a senior executive officer of several business segments within the General Electric Company, a publicly-held infrastructure and financial services company, with expertise across all areas of finance and accounting. Mr. Mahboob served as Chief Financial Officer, Eastern and African Growth Markets, of GE Healthcare from January 2013 to September 2015. From November 2010 to December 2012, Mr. Mahboob served as Chief Financial Officer, Global Ultrasound Business, of GE Healthcare. From September 2006 to October 2010, Mr. Mahboob served as Chief Financial Officer, Global Magnetic Resonance Business, of GE Healthcare. From October 2004 to August 2006, Mr. Mahboob served as Global Manufacturing Finance Manager of GE Advanced Materials. Prior to that Mr. Mahboob held several leadership positions within General Electric’s corporate audit staff. Mr. Mahboob received a Bachelor of Engineering in Computer Science from Bangalore University and an M.B.A. in Financial Markets and Institutions & Information Systems from the State University of New York, Buffalo, New York.

John Onopchenko

Mr. John Onopchenko has been appointed as Chief Operating Officer of the Company effective as of October 30, 2017. Mr. Onopchenko has almost thirty years of executive leadership experience in the medical device industry. Prior to joining the Company, Mr. Onopchenko served as Executive Vice President for Acutus Medical, Inc., a privately-held medical device company, since September 2016. At Acutus Medical, Mr, Onopchenko was responsible for program management/product development, quality, marketing and sales. Prior to Acutus Medical, Mr. Onopchenko served as Senior Vice President and Head of Therapy Strategy for Koninklijke Philips Electronics NV, a publicly-traded technology company (“Philips”), from March 2015 to September 2016. Prior to Philips, Mr. Onopchenko served as Executive Vice President (from April 2013 to November 2014) and Chief Operating Officer (from November 2014 to March 2015) of Volcano Corporation, a public-traded medical device company. While at Volcano, Mr. Onopchenko was responsible for its peripheral business unit, regulatory affairs, quality assurance, program management/product development, clinical affairs, business development, and its Axsun business unit. Prior to his employment with Volcano, Mr. Onopchenko served on Volcano’s Board of Directors for eleven years and also served as founder and managing director of Synergy Life Sciences Partners, LLC, an early-stage medical device venture capital fund. From 1996 to 2006, Mr. Onopchenko held senior positions at Johnson & Johnson, a publicly held medical device company, including serving as lead of medical device investments with Johnson & Johnson Development Corporation, and as Vice President of Worldwide Operations and Marketing for Advanced Sterilization Products, a Johnson & Johnson company. Mr. Onopchenko holds a Bachelor of Science degree from Ursinus College, and a Masters in Business Administration from the University of Chicago, Graduate School of Business.

Michael Chobotov

Mr. Michael V. Chobotov, Ph.D. serves as Chief Technology Officer of the Company. Dr. Chobotov co-founded TriVascular in 1998 and served as its President and Chief Executive Officer. Dr. Chobotov led TirVascular's spin-off from Boston Scientific Corporation in 2008, serving as its President and Chief Executive Office until 2012. Dr. Chobotov served as Chief Technology Officer of TriVascular from 2012 through February 2016 and served as a member of TriVascular’s board of directors until April 2014. Prior to co-founding TriVascular in 1998, Dr. Chobotov co-founded TransMotive Technologies, an engineering and product development consulting company. Previously, Dr. Chobotov served as Senior Vice President of Research & Development and a board member of U.S. Electricar, and Senior Systems Engineer at Hughes Space and Communications. He also led the design of the Lunar Prospector, which was subsequently implemented as the first NASA Discovery mission. Dr. Chobotov received his Ph.D. in Mechanical Engineering, his M.S. in Mechanical Engineering and his B.S. in Engineering and Applied Science, from the California Institute of Technology.

David Jennings

Mr. David M. Jennings serves as Vice President - Human Resources of Endologix Inc. Prior to joining us, Mr. Jennings spent twenty-five years as a Human Resources executive with the Johnson & Johnson Company, a publicly-held life sciences company, twelve of which were in the medical device space. At Johnson & Johnson, Mr. Jennings served as Vice President, Human Resources, for Advanced Sterilization Products in Irvine, California. Mr. Jennings also served for nearly ten years at Neutrogena Corporation in Los Angeles. Mr. Jennings has a proven track record of building high performance organizations in fast growing global companies. He has a diversity of health care experience, including in the areas of ophthalmology, surgical products, hospital products, instrument sterilization, pharmaceuticals and consumer products. After leaving Johnson &Johnson, Mr. Jennings held Human Resources Vice President roles in the entertainment industry as well as in a health care start-up venture in Southern California. Mr. Jennings holds a Bachelor’s Degree from California State University, Fullerton and a Masters in Business from Claremont Graduate University.

Amanda DePalma

Ms. Amanda L. DePalma serves as Vice President - Global Marketing of the company, since September 2014. Ms. DePalma’s responsibilities include global marketing, strategic planning and brand management. Ms. DePalma has more than 19 years of medical device marketing and sales experience. Prior to joining us, Ms. DePalma served as Senior Director, Global Strategic Marketing at Edwards Lifesciences, Inc. where she led global strategy, business development and branding efforts for the Critical Care business unit. From 2005 to 2011, Ms. DePalma held positions of increasing responsibility at Kimberly-Clark Healthcare (now Halyard Health), including serving as General Manager and Director of Global Strategic Marketing. Prior to that, Ms. DePalma held marketing positions at Guidant Corporation and Abbott Vascular. Ms. DePalma received a B.S. degree in Marketing and an M.B.A. from the University of Florida Warrington College of Business.

Meredith Huetter

Ms. Meredith O. Huetter is Vice President - Global Medical Affairs of the Company. Ms. Huetter joined us in February 2016 following our merger with TriVascular. Ms. Huetter joined TriVascular in November 2009 and served in various roles of increasing responsibility at TriVascular, including as Vice President, Clinical and Medical Affairs prior to the merger. Ms. Huetter has over 15 years of experience in the medical device industry. Prior to joining TriVascular, Ms. Huetter led the EndoVascular Product Marketing organization at Medtronic, Inc., where she directed several product introductions across the aortic product line. Ms. Huetter began her career with a focus on supply chain and healthcare at Ernst & Young LLP. Ms. Huetter received a B.S. degree in Industrial Engineering from Iowa State University.

Michael Maszy

Mr. Michael P. Maszy is an Vice President - Manufacturing of the Company. Mr. Maszy joined us in February 2016 following our merger with TriVascular. Mr. Maszy joined TriVascular in September 2010 and served in various roles of increasing responsibility with TriVascular, including as Vice President, Manufacturing prior to the merger. Mr. Maszy has over 16 years of experience in the medical device industry. Prior to joining TriVascular, Mr. Maszy served in various roles at Medtronic, Inc. from 2000 to 2010. Most recently, he led new product development teams at Medtronic Neurosurgery as Director of Project Management. Previously, Mr. Maszy led Operations for Medtronic Endovascular Innovations and also held positions in manufacturing engineering in Medtronic's Peripheral Vascular and Ear, Nose and Throat divisions. Mr. Maszy received an M.B.A. in Entrepreneurial Management from The Wharton School at The University of Pennsylvania and M.S. and B.S. degrees in Industrial and Systems Engineering from the University of Florida.

Laura Nagel

Ms. Laura Nagel is Vice President - Global Quality of the Company. Ms. Nagel joined us in January 2017 as our Vice President, Global Quality, bringing over 25 years of medical device experience, including specific experience with catheter-based technologies in class III cardiovascular implants. Most recently, Ms. Nagel served as Vice President, Quality Assurance at Direct Flow Medical, a privately-held medical device company developing and commercializing novel transcatheter heart valve products to treat structural heart disease. From 1997 to 2015, Ms. Nagel served in several leadership positions at Edwards Lifesciences and has broad experience in quality assurance, design validation, quality engineering, microbiology, compliance and post-market surveillance. Ms. Nagel also has extensive experience with international regulatory agencies. Ms. Nagel began her career at Allergan, Inc., serving in regulatory affairs, project management and product development positions from 1987 to 1997. Ms. Nagel received a Bachelor’s degree in Biological Science from the University of California, Berkeley.

Jeffrey Stelk

Mr. Jeffrey Stelk serves as Vice President - U.S. Sales of the Company. Mr. Stelk has over 25 years of sales and sales management experience in the medical device industry, including more than 16 years in the endovascular repair industry with us and Medtronic. Mr. Stelk is currently responsible for leading and managing the U.S. sales organization. During his tenure with us, Mr. Stelk has held various roles of increasing responsibility, including as Regional Sales Manager, Area Sales Manager and Director of Sales. In these roles, Mr. Stelk delivered significant sales growth by launching multiple new products and hiring, training and developing members of our direct sales team. Mr. Stelk holds a B.A. degree in Business Administration from St. Ambrose University in Davenport, Iowa.

W. Patrick Stephens

Mr. W. Patrick Stephens serves as Vice President - Research and Development of the Company. Mr. Stephens joined us in February 2016 following our merger with TriVascular. Mr. Stephens joined TriVascular in April 2008 and served in various roles of increasing responsibility with TriVascular, including as Vice President, Product Development prior to the merger. Mr. Stephens joined TriVascular in 1999 and served as a key member of the original TriVascular team through the acquisition by Boston Scientific in 2005. Mr. Stephens has more than 20 years of experience in the design, development and manufacturing of medical devices and previously served in roles of increasing responsibility at Medtronic, Boston Scientific and W.L. Gore. Mr. Stephens received an M.S. degree in Mechanical Engineering from the University of Arizona and a B.S. degree in Mechanical Engineering from the University of Colorado.

Joseph DeJohn

Mr. Joseph A. DeJohn serves as General Manager - Asia/Pacific and Latin America of Endologix Inc. Mr. DeJohn joined us in July 2008 as Vice President, Sales, and was subsequently promoted to Vice President, Global Sales. Mr. DeJohn has more than 20 years of sales management experience in the medical device industry, including 17 years at C.R. Bard. During his tenure at C.R. Bard, Mr. DeJohn held sales management positions with increasing responsibilities, serving the last six years as Vice President of Sales of the Peripheral Vascular Division. In this position, Mr. DeJohn was responsible for managing a 200-person sales organization and played a leadership role in strategic planning, budgeting, recruitment, professional development, national accounts, and customer service. Prior to that, Mr. DeJohn was Director of Sales of C.R. Bard’s Peripheral Technologies Division. Before joining C.R. Bard, Mr. DeJohn served five years with Bausch & Lomb Corporation in various sales management positions. Mr. DeJohn holds a B.S. in Education from Bowling Green State University.

Matthew Thompson

Dr. Matthew Thompson serves as Chief Medical Officer of the Company. Most recently, Dr. Thompson served as Professor of Vascular Surgery at St. George's University of London and St George's Vascular Institute. Dr. Thompson trained at Cambridge University, St. Bartholomew's Hospital, the University of Leicester and Adelaide. Dr. Thompson's awards include a Hunterian Professorship, the Moynihan traveling fellowship and the gold medal for the intercollegiate examination. Dr. Thompson is also the editor of the Oxford Textbook of Vascular Surgery and the Oxford Handbook of Vascular Surgery. He was Chair of the National Specialized Commissioning Clinical Reference Group for Vascular Services and is a founder of the British Society for Endovascular Therapy. Dr. Thompson is also a Council Member of the Vascular Society, Chairman of the Vascular Society Annual Scientific Meeting and elected President for 2018.

Christopher Chavez

Mr. Christopher G. Chavez serves as Independent Director of the Company. Mr. Chavez served on the board of directors of TriVascular, and as President, Chief Executive Officer and Chairman of the board of directors of TriVascular, from 2012 to February 2016. Mr. Chavez has over 30 years of leadership experience in the medical device industry. From 2005 through August 2011, Mr. Chavez served as President of the Neuromodulation Division of St. Jude Medical, Inc., or St. Jude Medical, and as Chief Executive Officer, President and a director of Advanced Neuromodulation Systems, or ANS, from 1998 until its acquisition by St. Jude Medical in 2005. Prior to ANS, Mr. Chavez spent 17 years at Johnson & Johnson, most recently as Vice President and General Manager of the Infection Control Business Unit. Mr. Chavez served on the board of directors of Advanced Medical Optics, Inc. from 2002 until it was acquired by Abbott Laboratories Inc. in 2009. Mr. Chavez has previously served as Chairman of the Medical Device Manufacturers Association and Chairman of the Dallas/Fort Worth Health Industry Council. Mr. Chavez received his M.B.A. from Harvard Business School and his Bachelors of Accountancy from New Mexico State University, Las Cruces.

Guido Neels

Mr. Guido J. Neels serves as an Independent Director of Endologix Inc., since December 10, 2010. Mr. Neels has been a Managing Director at Essex Woodlands Health Ventures, Inc., or Essex Woodlands, a venture capital firm, since 2006. Prior to joining Essex Woodlands, Mr. Neels served in a variety of management positions at Guidant Corporation, a developer of cardiovascular medical products. From July 2004 until retiring in November 2005, Mr. Neels served as Guidant’s Chief Operating Officer, where he was responsible for the global operations of Guidant’s four operating units: Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery, and Endovascular Solutions. From December 2002 to July 2004, Mr. Neels served as Guidant’s Group Chairman, Office of the President, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. In January 2000, Mr. Neels was named Guidant’s President, Europe, Middle East, Africa and Canada. In addition, Mr. Neels served as Guidant’s Vice President, Global Marketing, Vascular Intervention, from 1996 to 2000 and as Guidant’s General Manager, Germany and Central Europe, from 1994 to 1996. Mr. Neels has a business engineering degree from the University of Leuven in Belgium and an M.B.A. from the Stanford University Graduate School of Business. Mr. Neels served on the boards of directors of Biopure Corporation, a publicly-held medical device company, from 2005 to 2009, Lemaitre Vascular, Inc., a publicly-held medical device company, from 2006 to 2008, and Nellix, Inc., a privately-held medical device company, from 2006 until its acquisition by us in December 2010. Mr. Neels currently serves on the boards of directors of 480 Biomedical, Inc., Arsenal Medical, Inc., Bioventus LLC, and White Pine Medical, Inc., all privately-held medical device companies; and Entellus Medical, Inc. and Axotem, Inc, each a publicly-held medical device company.

Leslie Norwalk

Ms. Leslie V. Norwalk, Esq., serves as an Independent Director of the Company. Ms. Norwalk previously served as a member of the board of directors of Volcano Corporation, a publicly-held medical device company acquired by Phillips USA in February 2015. Since 2007, Ms. Norwalk has served as a Strategic Advisor and Strategic Counsel to Epstein Becker & Green, P.C., a law firm, and two consulting agencies: EBG Advisors, Inc., and National Health Advisors. Ms. Norwalk is an Operating Partner at Enhanced Equity Fund, L.P., a private equity firm, and also serves as an advisor to Warburg Pincus LLC, and Peloton Equity, both private equity firms. Previously, Ms. Norwalk served the Bush Administration as the Acting Administrator for the Centers for Medicare & Medicaid Services, or CMS, where she managed the day-to-day operations of Medicare, Medicaid, State Child Health Insurance Programs, the survey and certification of health care facilities and other federal health care initiatives. For four years prior to that, Ms. Norwalk was the agency’s Deputy Administrator, responsible for the implementation of the changes made under the Medicare Modernization Act, including the Medicare Prescription Drug Benefit. Prior to serving the Bush Administration, Ms. Norwalk practiced law in the Washington, D.C. office of Epstein Becker & Green, P.C. where she advised clients on a variety of health policy matters. She also served in the first Bush administration in the White House Office of Presidential Personnel and the Office of the U.S. Trade Representative. Ms. Norwalk serves on the boards of directors of NuVasive, Inc. and Providence Service Corp., both publicly-held companies, and on the boards of directors of several privately-held companies, and as a member of the International Advisory Council at APCO Worldwide Inc. Ms. Norwalk earned a J.D. degree from the George Mason University School of Law and a bachelor’s degree, cum laude, in Economics and International Relations from Wellesley College.

Gregory Waller

Mr. Gregory D. Waller, serves as Independent Director of Endologix, Inc., since November 2003. Mr. Waller also serves on the board of Sunshine Heart Corporation, a publicly traded company, as Audit Committee Chairman. From March 2006 until April 2011, Mr. Waller was Chief Financial Officer of Universal Building Products, a manufacturer of concrete construction accessories. Previous to that, Mr. Waller has been in retirement except for board directorships. Mr. Waller served as Vice President-Finance, Chief Financial Officer and Treasurer of Sybron Dental Specialties, Inc., a manufacturer and marketer of consumable dental products, from August 1993 until his retirement in May 2005 and was formerly the Vice President and Treasurer of Kerr, Ormco Corporation, and Metrex. Mr. Waller joined Ormco Corporation in December 1980 as Vice President and Controller and served as Vice President of Kerr European Operations from July 1989 to August 1993. Mr. Waller has an M.B.A. with a concentration in Accounting from California State University, Fullerton. Mr. Waller also served on the board of directors and audit committee of Cardiogenesis Corporation, a publicly-held company until its acquisition by Cryolife in 2011. Mr. Waller also served on the boards of directors of Alsius Corporation, a publicly-held company, from June 2007 until its acquisition by Zoll in September 2009, Biolase Technology, Inc., a publicly-held company, from October 2009 to August 2010, Clarient, Inc., a publicly-held company which was acquired by General Electric Company on December 22, 2010, and SenoRx, Inc., a publicly-held company which was acquired by C.R. Bard, Inc. on July 6, 2010.

Thomas Wilder

Mr. Thomas C. Wilder, III serves as an Independent Director of Endologix Inc., since May 2010. From February 2010 through July 2016, Mr. Wilder served as the Chief Executive Officer of Sequent Medical, Inc., a company dedicated to the development of innovative catheter-based neurovascular technologies. From May 2009 to February 2010, Mr. Wilder consulted with several medical device companies. From April 2006 to April 2009, Mr. Wilder served as the President and Chief Executive Officer of Photothera, Inc. From 2002 through January 2006, Mr. Wilder served at Micro Therapeutics, Inc. (MTIX) as President and Chief Executive Officer. Following the merger of Micro Therapeutics, Inc. into ev3 Inc. in January 2006, Mr. Wilder served as President, ev3 Neurovascular, until April 2006. Mr. Wilder served in positions of increasing responsibility at Medtronic, Inc. from 1991 through 2002, most recently as Vice President and General Manager of its endovascular stent grafts division. From 1986 to 1989, Mr. Wilder served in the Financial Statement Audit Practice of Price Waterhouse. Mr. Wilder has a B.A. in Economics from Stanford University and an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management. He currently serves on the board of directors of Penumbra, Inc., a publicly-held company, and served on the board of directors of Benvenue Medical, Inc., a privately-held company, until April 2017.

Thomas Zenty

Mr. Thomas F. Zenty, III., serves as an Independent Director of Endologix Inc. Mr. Zenty currently serves as the President and Chief Executive Officer of University Hospitals Health System, Inc., Cleveland, Ohio. Previously, Mr. Zenty held various executive positions with Cedars-Sinai Health System, St. Joseph’s Medical Center, a division of Dignity Health, Franciscan Health System of New Jersey and St. Mary Hospital, Connecticut. Mr. Zenty is Chairman of the Board of Western Reserve Assurance Company, Ltd. SPC, a privately-held insurance company, and chaired The Coalition to Protect America's Health Care. Mr. Zenty is a past board member of the American Hospital Association and has also served as a director on the board of Nationwide Financial Services, Inc. Mr. Zenty has held several academic positions with prestigious universities, including his current position as Adjunct Professor, Banking & Finance at Case Western Reserve University. He received a Master's degree in Public Administration from New York University, a Master's degree in Hospital Administration from Xavier University, and a Bachelor's degree in Health Planning from Pennsylvania State University.